Ratio of serum IgG6 to total IgG concentration and goiter size are independent factors in intractability of Graves' disease

Endocrine Journal

Volumn 54, Issue 6, 2007, Pages 887-894

  Santoh, Tomoko ^a   Watanabe, Mikio ^a   Kuroda, Shoko ^a   Ueda, Daishi ^a   Iwatani, Yoshinori ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Disease intractability; Goiter; Graves' disease; IgG3

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G; LIOTHYRONINE; THYROTROPIN; THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN; THYROTROPIN-BINDING INHIBITORY IMMUNOGLOBULIN; THYROXINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOITER; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; REMISSION; THYROTOXICOSIS; ADULT; BLOOD; IMMUNOLOGY; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS;

ADULT; AUTOANTIBODIES; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; IMMUNOGLOBULIN G; MALE; PROGNOSIS; STATISTICS, NONPARAMETRIC; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 40449094054     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07-005     Document Type: Article

References (24)

1. Weetman AP (2004) Autoimmune thyroid disease. Autoimmunity 37: 337-340.
2. Davies TF (2000) Pathogenesis of Graves' disease. In: Braverman LE and Utiger RD (eds) The thyroid - a fundamental and clinical text. Lippincott Williams & Wilkins, Philadelphia: 518-531.
3. Volpe R (2001) The immune system and its role in endocrine function. In: Becker KL (eds) Principles and practice of endocrinology and metabolism. Lippincott Williams & Wilkins, Philadelphia: 1770-1781.
4. + T cells in autoimmune thyroid disease. Clin Exp Immunol 136: 555-558.
5. + cells and thyroid autoantibodies in disease severity of Hashimoto's disease. Thyroid 12: 801-808.
6. Watanabe M, Yamamoto N, Maruoka H, Matsuzuka F, Miyauchi A, Iwatani Y (2003) Relation of CD30 molecules on T-cell subsets to the severity of autoimmune thyroid disease. Thyroid 13: 259-263.
7. Maruoka H, Watanabe M, Matsuzuka F, Takimoto T, Miyauchi A, Iwatani Y (2004) Increased intensities of Fas expression on peripheral T-cell subsets in severe autoimmune thyroid disease. Thyroid 14: 417-423.
8. Yamamoto N, Watanabe M, Matsuzuka F, Miyauchi A, Iwatani Y (2004) Lower concentration of serum soluble CD8 in severe Hashimoto's disease. Clin Exp Immunol 137: 601-605.
9. Yamada T, Komiya I, Miyahara Y, Komatsu M, Shima I, Inazawa T, Aizawa T (2006) Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. Endocr J 53: 783-788.
10. Okamoto Y, Tanigawa S, Ishikawa K, Hamada N (2006) TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 53: 467-472.
11. 6-secreting cells in intractable Graves' disease. Thyroid 13: 325-331.
12. Banchereau J (1995) Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitt 58-77.
13. 3. J Exp Med 179: 757-762.
14. Takeoka K, Watanabe M, Matsuzuka F, Miyauchi A, Iwatani Y (2004) Increase of serum interleukin-10 in intractable Graves' disease. Thyroid 14: 201-205.
15. Oppenheim JJ, Ruscetti FW (2001) Cytokines. In: Parslow TG, Stites DP, Terr AI and Imboden JB (eds) Medical Immunology. McGraw-Hill Co., Inc., New York: 148-166.
16. Iwatani Y, Watanabe M (1999) Normal mechanisms for self-tolerance. In: Volpe R (eds) Autoimmune Endocrinopathies. Humana Press, Totawa: 1-30.
17. Parslow TG (2001) Immunoglobulins & Immunoglobulin Genes. In: Parslow TG, Stites DP, Terr AI and Imboden JB (eds) Medical Immunology. McGraw-Hill Companies, Inc., New York: 95-114.
18. Weetman AP, Yateman ME, Ealey PA, Black CM, Reimer CB, Williams RC, Jr., Shine B, Marshall NJ (1990) Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest 86: 723-727.
19. Rodgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S (1987) Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 67: 82-88.
20. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.
21. Wang PW, Liu RT, Juo SH, Wang ST, Hu YH, Hsieh CJ, Chen MH, Chen IY, Wu CL (2004) Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal. J Clin Endocrinol Metab 89: 169-173.
22. Kim TY, Park YJ, Park do J, Chung HK, Kim WB, Kohn LD, Cho BY (2003) Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs. J Clin Endocrinol Metab 88: 117-124.
23. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA (2000) Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85: 1038-1042.
24. Glaser NS, Styne DM (1997) Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 82: 1719-1726.